Oct. 28 at 1:41 AM
$HRMY market share could be under threat in the next couple of years from
$TAK, then eventually
$ALKS and others. Of course HRMY does have its own orexin receptor-targeting drug, but it's a bit behind.
https://seekingalpha.com/article/4833747-harmony-biosciences-performing-commercially-but-competition-afoot
